Skip to main content
RVMD logo

RVMD · Revolution Medicines, Inc. · Webcasts, Transcripts & Audio

Track RVMD — free
$159.82 -2.87 (-1.76%) At close · Nov 18 Play latest call Q3 2026 earnings call transcript
Market Cap
$34.57B
Shares
216.29M
Volume · Nov 18 2.34M Avg daily vol (3M) 2.2M

Revolution Medicines, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Revolution Medicines, Inc. (RVMD), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Conference
Investor event
2026-11-16
Revolution Medicines, Inc. (RVMD) November 16, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-11-10
Revolution Medicines, Inc. (RVMD) November 10, 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-11-04
Revolution Medicines, Inc. (RVMD) Q3 2026 Earnings Call Transcript
Confident tone Colorectal cancer program Financial position and spending Pancreatic cancer pipeline
Revenue
$197.56M
Diluted EPS
$-1.90
Gross margin
99.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q2
2026-08-05
Revolution Medicines, Inc. (RVMD) Q2 2026 Earnings Call Transcript
Confident tone Expanded Access Program (EAP) Pancreatic cancer / PDAC launch Broader pipeline / RAS(ON) inhibitors
Diluted EPS
$-3.06
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-05-31
Revolution Medicines, Inc. (RVMD) May 31, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-06
Revolution Medicines, Inc. (RVMD) Q1 2026 Earnings Call Transcript
Confident tone RASolute 302 Phase 3 results in pancreatic cancer Clinical and competitive uncertainties Non-small cell lung cancer development
Diluted EPS
$-2.29
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Revolution Medicines, Inc. (RVMD) Q4 2025 Earnings Call Transcript
Confident tone RMC-6236 (daraxonrasib) combination strategies Zoldonrasib development in PDAC Daraxonrasib in pancreatic cancer (RASolute 302/303/304)
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Revolution Medicines, Inc. (RVMD) Q3 2025 Earnings Call Transcript
Confident tone Daraxonrasib in pancreatic cancer (PDAC) Combination strategies and resistance mechanisms Efficacy and durability data
Revenue
$0
Diluted EPS
$-1.61
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Revolution Medicines, Inc. (RVMD) Q2 2025 Earnings Call Transcript
Confident tone Pancreatic cancer program (daraxonrasib) Non-small cell lung cancer (NSCLC) Clinical collaborations and combinations
Diluted EPS
$-1.31
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Revolution Medicines, Inc. (RVMD) Q1 2025 Earnings Call Transcript
Confident tone Non-small cell lung cancer strategy RAS(ON) inhibitor portfolio Pancreatic cancer development
Diluted EPS
$-1.13
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
Revolution Medicines, Inc. (RVMD) Q4 2024 Earnings Call Transcript
Confident tone RAS(ON) inhibitor pipeline progress Combination strategies Pivotal/registrational trials execution
Revenue
$0*
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Call Transcript
Confident tone RMC-6236 in pancreatic cancer (PDAC) Combination strategy and clinical collaborations Non-small cell lung cancer strategy
Revenue
$0
Diluted EPS
$-0.94
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Revolution Medicines, Inc. (RVMD) Q2 2024 Earnings Call Transcript
Confident tone RMC-6236 pancreatic cancer data and registrational plans Combination studies and early-line expansion RAS(ON) mutant-selective inhibitors (RMC-6291, RMC-9805)
Revenue
$0
▼ 100% YoY
Diluted EPS
$-0.81
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Revolution Medicines, Inc. (RVMD) Q1 2024 Earnings Call Transcript
Confident tone RMC-6236 combination regimens RMC-6236 pivotal trial strategy RMC-6291 and RMC-9805 mutant-selective inhibitors
Revenue
$0
▼ 100% YoY
Diluted EPS
$-0.70
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-26
Revolution Medicines, Inc. (RVMD) Q4 2023 Earnings Call Transcript
Confident tone RMC-6236 pivotal trial plans Financial strength and runway RMC-6291 G12C selective inhibitor
Revenue
$742,000*
▼ 95.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Revolution Medicines, Inc. (RVMD) Q3 2023 Earnings Call Transcript
Revenue
$0
▼ 100% YoY
Diluted EPS
$-0.99
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Revolution Medicines, Inc. (RVMD) Q2 2023 Earnings Call Transcript
Revenue
$3.82M
▼ 58.1% YoY
Diluted EPS
$-0.92
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Revolution Medicines, Inc. (RVMD) Q1 2023 Earnings Call Transcript
Revenue
$7.01M
▼ 7.4% YoY
Diluted EPS
$-0.72
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-27
Revolution Medicines, Inc. (RVMD) Q4 2022 Earnings Call Transcript
Revenue
$15.33M*
▲ 62.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-07
Revolution Medicines, Inc. (RVMD) Q3 2022 Earnings Call Transcript
Revenue
$3.36M
▲ 204.8% YoY
Diluted EPS
$-0.87
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Revolution Medicines, Inc. (RVMD) Q2 2022 Earnings Call Transcript
Revenue
$9.12M
▲ 4.8% YoY
Diluted EPS
$-0.82
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Revolution Medicines, Inc. (RVMD) Q1 2022 Earnings Call Transcript
Revenue
$7.58M
▼ 25.2% YoY
Diluted EPS
$-0.78
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-11
Revolution Medicines, Inc. (RVMD) Q4 2021 Earnings Call Transcript
Revenue
$9.46M*
▲ 8.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Revolution Medicines, Inc. (RVMD) Q3 2021 Earnings Call Transcript
Revenue
$1.10M
▼ 91.3% YoY
Diluted EPS
$-0.72
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-11
Revolution Medicines, Inc. (RVMD) Q2 2021 Earnings Call
Revenue
$8.70M
▼ 13.2% YoY
Diluted EPS
$-0.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–25 of 25 webcasts
Key facts CIK 1628171 CUSIP 76155X100 13F (30d) 719 filings 681 filers Visit website Investor relations